{"analyses":[{"ciLowerLimit":"0.08","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.21","estimateComment":"A hazard ratio \\< 1 favours osimertinib","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.001","paramType":"Hazard Ratio (HR)","paramValue":"0.13","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA - Not calculated as insufficient number of events to enable the upper limit of 95% confidence interval to be calculated","groupId":"OG000","lowerLimit":"38.87","upperLimit":"NA","value":"43.83"},{"groupId":"OG001","lowerLimit":"6.60","upperLimit":"11.53","value":"9.46"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"143"},{"groupId":"OG001","value":"73"}],"units":"Participants"}],"description":"Time from the date of randomisation to the earlier of the date of anti-cancer therapy start date following study drug discontinuation or death","dispersionType":"95% Confidence Interval","groups":[{"description":"80mg once daily tablet","id":"OG000","title":"Osimertinib"},{"description":"Matching Placebo","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Time from randomisation to the start of first subsequent anti-cancer therapy or death. Assessed up to date of DCO (05Jan24) to a maximum of approximately 63 months","title":"Time to First Subsequent Treatment","type":"SECONDARY","unitOfMeasure":"Months"}